Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1290964
Isis Pharmaceuticals, Inc. (ISIS) - Financial and Strategic SWOT Analysis Review
Description:
Summary
Isis Pharmaceuticals, Inc. (Isis) is a pharmaceutical company specialized in antisense technology. The company carries out the discovery and development of new class antisense drugs that address significant unmet medical needs. Antisense technology is a direct route from genomics to drugs. The product pipeline of the company focuses on various therapeutic areas, namely, cardiovascular, cancer, metabolic, neurodegenerative, inflammatory and other diseases. Isis lead product KYNAMRO is in Phase III of clinical trial and being developed under collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol.
Isis Pharmaceuticals, Inc. Key Recent Developments
Feb 28, 2013: Isis Reports Revenue Of $102m In 2012
Feb 04, 2013: Rosalind Franklin University Scientists Prevent Development Of Deafness In Animals Engineered To Have Usher Syndrome
Nov 06, 2012: Isis Reports Revenue Of $11.6m In Q3 2012
Oct 24, 2012: Isis Pharma To Receive $1.1m Milestone Payment From Alnylam Pharma
Sep 25, 2012: Isis Pharma Discovers User Access With Varonis's DatAdvantage
This comprehensive SWOT profile of Isis Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Isis Pharmaceuticals, Inc. (Isis) is a pharmaceutical company specialized in antisense technology. The company carries out the discovery and development of new class antisense drugs that address significant unmet medical needs. Antisense technology is a direct route from genomics to drugs. The product pipeline of the company focuses on various therapeutic areas, namely, cardiovascular, cancer, metabolic, neurodegenerative, inflammatory and other diseases. Isis lead product KYNAMRO is in Phase III of clinical trial and being developed under collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol.
Isis Pharmaceuticals, Inc. Key Recent Developments
Feb 28, 2013: Isis Reports Revenue Of $102m In 2012
Feb 04, 2013: Rosalind Franklin University Scientists Prevent Development Of Deafness In Animals Engineered To Have Usher Syndrome
Nov 06, 2012: Isis Reports Revenue Of $11.6m In Q3 2012
Oct 24, 2012: Isis Pharma To Receive $1.1m Milestone Payment From Alnylam Pharma
Sep 25, 2012: Isis Pharma Discovers User Access With Varonis's DatAdvantage
This comprehensive SWOT profile of Isis Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Contents:
List of Tables
List of Figures
Section 1 - About the Company
Isis Pharmaceuticals, Inc. - Key Facts
Isis Pharmaceuticals, Inc. - Key Employees
Isis Pharmaceuticals, Inc. - Key Employee Biographies
Isis Pharmaceuticals, Inc. - Major Products and Services
Isis Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
Isis Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Isis Pharmaceuticals, Inc., Pipeline Products by Development Phase
Isis Pharmaceuticals, Inc. - History
Isis Pharmaceuticals, Inc. - Company Statement
Isis Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Isis Pharmaceuticals, Inc. - Business Description
Isis Pharmaceuticals, Inc. - Corporate Strategy
Isis Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Isis Pharmaceuticals, Inc. - Strengths
Strength - Patented Antisense Technology
Strength - Intellectual Property
Strength - Strategic Collaborations
Isis Pharmaceuticals, Inc. - Weaknesses
Weakness - Limited Manufacturing Facilities
Weakness - Weak Financial Performance
Weakness - Legal Proceedings
Isis Pharmaceuticals, Inc. - Opportunities
Opportunity - Demographic Trends
Opportunity - Product Pipeline
Opportunity - ISIS-SMN: Orphan Drug Designation
Isis Pharmaceuticals, Inc. - Threats
Threat - Increased Pricing Control
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
Isis Pharmaceuticals, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Isis Pharmaceuticals, Inc., Recent Developments
Feb 28, 2013: Isis Reports Revenue Of $102m In 2012
Feb 04, 2013: Rosalind Franklin University Scientists Prevent Development Of Deafness In Animals Engineered To Have Usher Syndrome
Nov 06, 2012: Isis Reports Revenue Of $11.6m In Q3 2012
Oct 24, 2012: Isis Pharma To Receive $1.1m Milestone Payment From Alnylam Pharma
Sep 25, 2012: Isis Pharma Discovers User Access With Varonis's DatAdvantage
Sep 06, 2012: Isis Pharma Expands Use Of BioClinica Express EDC
Aug 30, 2012: Isis Pharma Demonstrates Single-Stranded RNA-Like Antisense Technology To Activate RNAi Pathway
Aug 28, 2012: Isis Pharma To Receive $1.4m From Alnylam Pharma
Aug 06, 2012: Isis Pharma Reports Revenue Of $47.3m In Q2 2012
Aug 04, 2012: European Regulatory Authorities Approve Isis's Manufacturing Facility
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer
List of Tables
Isis Pharmaceuticals, Inc., Key Facts
Isis Pharmaceuticals, Inc., Key Employees
Isis Pharmaceuticals, Inc., Key Employee Biographies
Isis Pharmaceuticals, Inc., Major Products and Services
Isis Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
Isis Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
Isis Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
Isis Pharmaceuticals, Inc., History
Isis Pharmaceuticals, Inc., Subsidiaries
Isis Pharmaceuticals, Inc., Key Competitors
Isis Pharmaceuticals, Inc., Ratios based on current share price
Isis Pharmaceuticals, Inc., Annual Ratios
Isis Pharmaceuticals, Inc., Interim Ratios
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Isis Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Isis Pharmaceuticals, Inc., Pipeline Products by Development Phase
Isis Pharmaceuticals, Inc., Performance Chart (2008 - 2012)
Isis Pharmaceuticals, Inc., Ratio Charts
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013
List of Figures
Section 1 - About the Company
Isis Pharmaceuticals, Inc. - Key Facts
Isis Pharmaceuticals, Inc. - Key Employees
Isis Pharmaceuticals, Inc. - Key Employee Biographies
Isis Pharmaceuticals, Inc. - Major Products and Services
Isis Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
Isis Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Isis Pharmaceuticals, Inc., Pipeline Products by Development Phase
Isis Pharmaceuticals, Inc. - History
Isis Pharmaceuticals, Inc. - Company Statement
Isis Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Isis Pharmaceuticals, Inc. - Business Description
Isis Pharmaceuticals, Inc. - Corporate Strategy
Isis Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Isis Pharmaceuticals, Inc. - Strengths
Strength - Patented Antisense Technology
Strength - Intellectual Property
Strength - Strategic Collaborations
Isis Pharmaceuticals, Inc. - Weaknesses
Weakness - Limited Manufacturing Facilities
Weakness - Weak Financial Performance
Weakness - Legal Proceedings
Isis Pharmaceuticals, Inc. - Opportunities
Opportunity - Demographic Trends
Opportunity - Product Pipeline
Opportunity - ISIS-SMN: Orphan Drug Designation
Isis Pharmaceuticals, Inc. - Threats
Threat - Increased Pricing Control
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
Isis Pharmaceuticals, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Isis Pharmaceuticals, Inc., Recent Developments
Feb 28, 2013: Isis Reports Revenue Of $102m In 2012
Feb 04, 2013: Rosalind Franklin University Scientists Prevent Development Of Deafness In Animals Engineered To Have Usher Syndrome
Nov 06, 2012: Isis Reports Revenue Of $11.6m In Q3 2012
Oct 24, 2012: Isis Pharma To Receive $1.1m Milestone Payment From Alnylam Pharma
Sep 25, 2012: Isis Pharma Discovers User Access With Varonis's DatAdvantage
Sep 06, 2012: Isis Pharma Expands Use Of BioClinica Express EDC
Aug 30, 2012: Isis Pharma Demonstrates Single-Stranded RNA-Like Antisense Technology To Activate RNAi Pathway
Aug 28, 2012: Isis Pharma To Receive $1.4m From Alnylam Pharma
Aug 06, 2012: Isis Pharma Reports Revenue Of $47.3m In Q2 2012
Aug 04, 2012: European Regulatory Authorities Approve Isis's Manufacturing Facility
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer
List of Tables
Isis Pharmaceuticals, Inc., Key Facts
Isis Pharmaceuticals, Inc., Key Employees
Isis Pharmaceuticals, Inc., Key Employee Biographies
Isis Pharmaceuticals, Inc., Major Products and Services
Isis Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
Isis Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
Isis Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
Isis Pharmaceuticals, Inc., History
Isis Pharmaceuticals, Inc., Subsidiaries
Isis Pharmaceuticals, Inc., Key Competitors
Isis Pharmaceuticals, Inc., Ratios based on current share price
Isis Pharmaceuticals, Inc., Annual Ratios
Isis Pharmaceuticals, Inc., Interim Ratios
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Isis Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Isis Pharmaceuticals, Inc., Pipeline Products by Development Phase
Isis Pharmaceuticals, Inc., Performance Chart (2008 - 2012)
Isis Pharmaceuticals, Inc., Ratio Charts
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013
Companies Mentioned
Genta Incorporated
Enzo Biochem, Inc.
AVI BioPharma Inc.
XOMA Ltd.
Novartis AG
Idenix Pharmaceuticals, Inc.
Enzo Biochem, Inc.
AVI BioPharma Inc.
XOMA Ltd.
Novartis AG
Idenix Pharmaceuticals, Inc.
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1290964
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Thursday, June 20, 2013
9:27:06 AM
9:27:06 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Isis Pharmaceuticals, Inc. (ISIS) - Financial and Strategic SWOT Analysis Review
Web Address
http://www.researchandmarkets.com/reports/1290964
Office Code
OC8DIQQLQSRPQR
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price |
|---|---|---|
| Electronic (PDF) - Single User |
|
EUR 96 |
| Electronic (PDF) - Site License |
|
EUR 191 |
| Electronic (PDF) - Enterprisewide |
|
EUR 287 |
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Thursday, June 20, 2013
9:27:06 AM
9:27:06 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp